Q2 2024 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089632
$1.57B
Reported value
35
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $334.2M | 21.3% | 8,493,321 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $94.1M | 5.99% | 4,026,331 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $92.4M | 5.88% | 4,400,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $87.3M | 5.56% | 12,762,462 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $76.7M | 4.89% | 2,173,913 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $74.7M | 4.76% | 1,263,214 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $73.6M | 4.69% | 6,249,731 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $63.8M | 4.07% | 3,395,606 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $63.1M | 4.02% | 2,685,448 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $54.2M | 3.45% | 2,094,373 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $50.5M | 3.22% | 3,882,671 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $47.9M | 3.05% | 5,684,167 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $44.6M | 2.84% | 9,542,871 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $38.3M | 2.44% | 16,216,216 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $32.8M | 2.09% | 3,608,645 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $32.7M | 2.09% | 1,818,182 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $31.1M | 1.98% | 4,394,527 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $29.2M | 1.86% | 706,131 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $26.6M | 1.70% | 2,825,983 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $24.1M | 1.53% | 1,379,965 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $23.2M | 1.48% | 3,410,058 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $22.8M | 1.45% | 11,328,000 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $21.1M | 1.34% | 6,023,166 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $20.2M | 1.28% | 9,000,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $17.8M | 1.13% | 1,345,780 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $16.7M | 1.06% | 627,788 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $14.4M | 0.92% | 5,555,555 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $13.7M | 0.88% | 5,389,259 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $11.7M | 0.75% | 1,563,952 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $10.2M | 0.65% | 3,422,637 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $10.1M | 0.64% | 1,467,048 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.5M | 0.48% | 750,000 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $4.8M | 0.31% | 1,555,556 | Common | SOLE |
| 00211Y506 | ABIOEUR | ARCA BIOPHARMA INC | $3.3M | 0.21% | 866,375 | Common | SOLE |
| G1933S101 | CASIF | CASI PHARMACEUTICALS INC | $614,273 | 0.04% | 111,686 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.